Search Results for 'rtog 3503'

Search For:

Refine by Dates:

Past 7 Days | Past 30 Days

Refine By Content:

Testing

FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune

The RTOG 3503 Phase 2 trial is the first consortium study to test tumor treating fields therapy.

Novocure 04.28.16
Testing

FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune

The RTOG 3503 Phase 2 trial is the first consortium study to test tumor treating fields therapy.

Novocure 04.27.16

Loading, Please Wait..